BioNetwork 2021

October 06 - 08, 2021

The Ritz-Carlton Laguna Niguel, CA

Day One


Innovation in the BioPharma Partnering Landscape

Wednesday, October 23, 2019

7:00 am - 8:05 am Full Breakfast Buffet & Registration

8:05 am - 8:15 am Welcome Remarks

Matt Millman, Life Science Research Director at BioNetwork 2019

Matt Millman

Life Science Research Director
BioNetwork 2019

8:15 am - 8:30 am Chairperson’s Opening Remarks

Christopher Leo, Senior Vice President at Back Bay Life Science Advisors

Christopher Leo

Senior Vice President
Back Bay Life Science Advisors

8:30 am - 9:00 am Keynote: J&J’s New Paradigm for External Innovation


Healthcare has been undergoing dramatic changes due to a congruence of three trends: the explosion of scientific knowledge and previously unimaginable enabling technologies; the empowerment and broad use of self-quantification for health information by consumers and the exploitation of big data sets by industry to drive new healthcare related insights; and, finally, pressures from and on the healthcare system to adopt new models, including stronger focus on early detection and prevention.

In this session, we will hear how Johnson & Johnson harnesses its expertise in pharma, medical device and consumer products to transform the innovation landscape to meet patient, consumer, and market needs in this new reality.

Michal Preminger, Head, Johnson & Johnson Innovation, East North America at Johnson & Johnson

Michal Preminger

Head, Johnson & Johnson Innovation, East North America
Johnson & Johnson

9:00 am - 9:30 am Keynote: Genomic Prediction of Complex Traits and Disease Risks via AI and Large Genomic Datasets

Steve Hsu is SVP for Research and Professor of Theoretical Physics at Michigan State University. He is a leader in the use of AI in computational genomics. His lab produced the first accurate predictors for human height and other complex traits, including disease risks such as diabetes, atrial fibrillation, breast cancer, and hypothyroidism. He is the founder of biotech startups Genomic Prediction (advanced genetic testing for IVF) and Othram (DNA forensics for law enforcement and military applications).

This talk is divided into two parts. The first gives an overview of the rapidly advancing area of genomic prediction of disease risks using polygenic scores. We can now identify risk outliers (e.g., with 5 or 10 times normal risk) for about 20 common disease conditions, ranging from diabetes to heart diseases to breast cancer, using inexpensive SNP genotypes (i.e., as offered by 23andMe).

We can also predict some complex quantitative traits (e.g., adult height with accuracy of few cm, using ~20k SNPs). This talk will discuss application of these results in precision medicine as well as embryo selection in IVF, and give some details concerning genetic architecture. The second part covers the AI/ML used to build these predictors, with an emphasis on "sparse learning" and phase transitions in high dimensional statistics.

Steve Hsu, SVP, Office of Research and Innovation at Michigan State University

Steve Hsu

SVP, Office of Research and Innovation
Michigan State University

9:30 am - 10:00 am Morning Refreshment Break & Partnering Opens


10:00 am - 10:30 am Morning Refreshment Break & Partnering Opens

10:00 am - 12:30 pm 1:1 Partnering

There is a mad dash to utilize innovative technology for drug development and investment with the hopes for increased speed & efficiency.  However, a knowledge gap exists on the availability and viability of these technologies.  This panel discussion will share the perspectives from fledgling technology innovators and industry representatives on what boxes must be checked off in order to be successful when partnering with high technology.
Jennifer Leeds, Head, West Coast Search and Evaluation at Novartis

Jennifer Leeds

Head, West Coast Search and Evaluation
Novartis

Jeff Elton, Chief Executive Officer at Concerto Health AI

Jeff Elton

Chief Executive Officer
Concerto Health AI

Ron Alfa, Senior Vice President of Translational Discovery & Chief Evangelist at Recursion Pharma

Ron Alfa

Senior Vice President of Translational Discovery & Chief Evangelist
Recursion Pharma

Christopher Leo, Senior Vice President at Back Bay Life Science Advisors

Christopher Leo

Senior Vice President
Back Bay Life Science Advisors

Jane Rhodes, Chief Business Officer at Verge Genomics

Jane Rhodes

Chief Business Officer
Verge Genomics

10:00 am - 12:30 pm 1:1 Partnering

11:00 am - 11:15 am Biotech Spotlight Session: Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.
Lisa Conte, Founder, President and Chief Executive Officer at Jaguar Health

Lisa Conte

Founder, President and Chief Executive Officer
Jaguar Health

10:00 am - 12:30 pm 1:1 Partnering

11:15 am - 11:30 am Biotech Spotlight Session: RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

Isaac Bright, Co-Founder and Chief Executive Officer at RubrYc Therapeutics

Isaac Bright

Co-Founder and Chief Executive Officer
RubrYc Therapeutics

10:00 am - 12:30 pm 1:1 Partnering

The highly competitive immuno-oncology market is poised for massive growth for all the right reasons.  As opposed to conventional therapies like radiation, immunotherapy has shown to have low-toxicity, higher approval rates and subsequently rapid clinical adoption.  This panel will discuss the current standing and opportunities in the immunotherapy market as well as enabling deal structures that best allow promising candidates to get to market.
Hemmie Chang, Chair, Licensing & Strategic Alliances Practice Group at Foley Hoag

Hemmie Chang

Chair, Licensing & Strategic Alliances Practice Group
Foley Hoag

Melissa Fitzgerald, Head of Oncology Search & Evaluation at Halozyme Therapeutics

Melissa Fitzgerald

Head of Oncology Search & Evaluation
Halozyme Therapeutics

Syed Kazmi, Global Head, Business Development & Licensing, Oncology at Novartis

Syed Kazmi

Global Head, Business Development & Licensing, Oncology
Novartis

Michael Andrew Johnson, VP, Business Development at Eli Lilly

Michael Andrew Johnson

VP, Business Development
Eli Lilly

10:00 am - 12:30 pm 1:1 Partnering

12:00 pm - 12:15 pm Biotech Spotlight Session: Modulation Therapeutics

Lori Hazlehurst, CEO at Modulation Therapeutics

Lori Hazlehurst

CEO
Modulation Therapeutics

12:15 pm - 12:30 pm Biotech Spotlight Session: Open

10:00 am - 12:30 pm 1:1 Partnering

12:30 pm - 1:30 pm Networking Lunch in the Courtyard

To achieve success, the right partnership “fit” is critical but how can stakeholders best identify a strong cultural match while navigating the current landscape of both market and company-specific challenges?  Even in the strongest partnerships, a variety of hurdles can arise that terminate a deal.  The art of due diligence to address financial resources, manufacturing capabilities, regulatory consideration and many more must be addressed properly to ensure contractual deliverables that nurture success.  This session will review the approach to due diligence with specific how-to’s and how-nots shared.
Robert Bagdorf, VP & Group Lead, Search and Evaluation, Worldwide Business Development at Pfizer Inc.

Robert Bagdorf

VP & Group Lead, Search and Evaluation, Worldwide Business Development
Pfizer Inc.

Wesley Galamb, US Lead, Business Development & Innovation at Novo Nordisk

Wesley Galamb

US Lead, Business Development & Innovation
Novo Nordisk

Vanitha Sekar, Executive Director, Business Development & Licensing at Merck Research Labs

Vanitha Sekar

Executive Director, Business Development & Licensing
Merck Research Labs

Hannah Cabot, Associate M&A at Back Bay Life Science Advisors

Hannah Cabot

Associate M&A
Back Bay Life Science Advisors

1:30 pm - 5:00 pm 1:1 Partnering

2:00 pm - 2:15 pm Biotech Spotlight Session: For-Robin

For-Robin, Inc, founded in 2012 and named in honor of the founder’s sister who died at age 31 of breast cancer, is an antibody immunotherapy company whose primary mission is developing treatments for breast and lung cancer patients.
Kate Rittenhouse-Olson, Founder at For-Robin, Inc

Kate Rittenhouse-Olson

Founder
For-Robin, Inc

1:30 pm - 5:00 pm 1:1 Partnering

2:15 pm - 2:30 pm Biotech Spotlight Session: OncoNano Medicine

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. OncoNano is the first company to advance product candidates using pH as a biomarker for cancer immunotherapy, therapeutic use and intra-operative imaging based on its pH-sensitive micelle technology.

Ravi Srinivasan

Founder, President, CEO
OncoNano Medicine

1:30 pm - 5:00 pm 1:1 Partnering

The investment and funding landscape has evolved rapidly and deal structures have progressed far from the one-size-fits-all approach. This session will examine some creative deals including co-development and co-promotional rights. Lessons will be shared from unconventional deals that have taken place in the past couple of years. 

Learn how the biopharma funding landscape is still evolving and how biotechs can take
advantage of the current funding environment.

Neena Kadaba, Director, Science at Quark Venture

Neena Kadaba

Director, Science
Quark Venture

Laszlo Kiss, Executive Director, WRD and Principal at Pfizer Ventures

Laszlo Kiss

Executive Director, WRD and Principal
Pfizer Ventures

Scott Shaunessy, CEO at ideaPoint

Scott Shaunessy

CEO
ideaPoint

1:30 pm - 5:00 pm 1:1 Partnering

3:00 pm - 3:15 pm Biotech Spotlight: Biotech Spotlight: CytomX

Nick Galli, Chief Business Officer at CytomX

Nick Galli

Chief Business Officer
CytomX

3:15 pm - 3:30 pm Biotech Spotlight: IMEC

Winny Tan, Senior Manager, Strategic Alliances at IMEC

Winny Tan

Senior Manager, Strategic Alliances
IMEC

1:30 pm - 5:00 pm 1:1 Partnering

3:30 pm - 4:00 pm Afternoon Refreshment Break

1:30 pm - 5:00 pm 1:1 Partnering

4:00 pm - 4:30 pm Biotech Spotlights

1:30 pm - 5:00 pm 1:1 Partnering

4:30 pm - 5:00 pm Deal Spotlight: Tales from the Trenches: A Brief History of how Teneobio and Abbvie Came Together to Become Partners in the Development of TNB-383B, A Novel Bispecific T Cell Engager for Multiple Myeloma.

This session will discuss:
•History of how the deal came into existence
•What each partner brings to the table 
•What specifically TNB-383B is, and why working on this program collaboratively was an attractive proposition to both parties
•How this deal augments AbbVie’s Oncology pipeline  
•What value and differentiated value proposition both companies believe TNB-383B could bring to patients

Niels Emmerich, VP, Global Head Search & Evaluation at Abbvie

Niels Emmerich

VP, Global Head Search & Evaluation
Abbvie

Roland Buelow, CEO at TeneoBio

Roland Buelow

CEO
TeneoBio

1:30 pm - 5:00 pm 1:1 Partnering

5:00 pm - 6:00 pm Veranda Sunset Reception Overlooking the Laguna Hills

6:00 pm - 6:00 pm End of BioNetwork Day One